Melatonin's role as a co-adjuvant treatment in colonic diseases

A review

Eduardo Esteban-Zubero, Laura López-Pingarrón, Moisés Alejandro Alatorre-Jiménez, Purificación Ochoa-Moneo, Celia Buisac-Ramón, Miguel Rivas-Jiménez, Silvia Castán-Ruiz, Ángel Antoñanzas-Lombarte, Dun Xian Tan, José Joaquín García, Russel J Reiter

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Melatonin is produced in the pineal gland as well as many other organs, including the enterochromaffin cells of the digestive mucosa. Melatonin is a powerful antioxidant that resists oxidative stress due to its capacity to directly scavenge reactive species, to modulate the antioxidant defense system by increasing the activities of antioxidant enzymes, and to stimulate the innate immune response through its direct and indirect actions. In addition, the dysregulation of the circadian system is observed to be related with alterations in colonic motility and cell disruptions due to the modifications of clock genes expression. In the gastrointestinal tract, the activities of melatonin are mediated by melatonin receptors (MT2), serotonin (5-HT), and cholecystokinin B (CCK2) receptors and via receptor-independent processes. The levels of melatonin in the gastrointestinal tract exceed by 10–100 times the blood concentrations. Also, there is an estimated 400 times more melatonin in the gut than in the pineal gland. Gut melatonin secretion is suggested to be influenced by the food intake. Low dose melatonin treatment accelerates intestinal transit time whereas high doses may decrease gut motility. Melatonin has been studied as a co-adjuvant treatment in several gastrointestinal diseases including irritable bowel syndrome (IBS), constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), Crohn's disease, ulcerative colitis, and necrotizing enterocolitis. The purpose of this review is to provide information regarding the potential benefits of melatonin as a co-adjuvant treatment in gastrointestinal diseases, especially IBS, Crohn's disease, ulcerative colitis, and necrotizing enterocolitis.

Original languageEnglish (US)
Pages (from-to)72-81
Number of pages10
JournalLife Sciences
Volume170
DOIs
StatePublished - Feb 1 2017

Fingerprint

Colonic Diseases
Melatonin
Irritable Bowel Syndrome
Cholecystokinin B Receptor
Necrotizing Enterocolitis
Pineal Gland
Antioxidants
Gastrointestinal Diseases
Ulcerative Colitis
Crohn Disease
Gastrointestinal Tract
Serotonin
Chronobiology Disorders
Melatonin MT2 Receptor
Enterochromaffin Cells
Oxidative stress
Cholecystokinin
Constipation
Innate Immunity
Gene expression

Keywords

  • Crohn's disease
  • Gastrointestinal diseases
  • Irritable bowel syndrome
  • Melatonin
  • Necrotizing enterocolitis
  • Ulcerative colitis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Esteban-Zubero, E., López-Pingarrón, L., Alatorre-Jiménez, M. A., Ochoa-Moneo, P., Buisac-Ramón, C., Rivas-Jiménez, M., ... Reiter, R. J. (2017). Melatonin's role as a co-adjuvant treatment in colonic diseases: A review. Life Sciences, 170, 72-81. https://doi.org/10.1016/j.lfs.2016.11.031

Melatonin's role as a co-adjuvant treatment in colonic diseases : A review. / Esteban-Zubero, Eduardo; López-Pingarrón, Laura; Alatorre-Jiménez, Moisés Alejandro; Ochoa-Moneo, Purificación; Buisac-Ramón, Celia; Rivas-Jiménez, Miguel; Castán-Ruiz, Silvia; Antoñanzas-Lombarte, Ángel; Tan, Dun Xian; García, José Joaquín; Reiter, Russel J.

In: Life Sciences, Vol. 170, 01.02.2017, p. 72-81.

Research output: Contribution to journalReview article

Esteban-Zubero, E, López-Pingarrón, L, Alatorre-Jiménez, MA, Ochoa-Moneo, P, Buisac-Ramón, C, Rivas-Jiménez, M, Castán-Ruiz, S, Antoñanzas-Lombarte, Á, Tan, DX, García, JJ & Reiter, RJ 2017, 'Melatonin's role as a co-adjuvant treatment in colonic diseases: A review', Life Sciences, vol. 170, pp. 72-81. https://doi.org/10.1016/j.lfs.2016.11.031
Esteban-Zubero E, López-Pingarrón L, Alatorre-Jiménez MA, Ochoa-Moneo P, Buisac-Ramón C, Rivas-Jiménez M et al. Melatonin's role as a co-adjuvant treatment in colonic diseases: A review. Life Sciences. 2017 Feb 1;170:72-81. https://doi.org/10.1016/j.lfs.2016.11.031
Esteban-Zubero, Eduardo ; López-Pingarrón, Laura ; Alatorre-Jiménez, Moisés Alejandro ; Ochoa-Moneo, Purificación ; Buisac-Ramón, Celia ; Rivas-Jiménez, Miguel ; Castán-Ruiz, Silvia ; Antoñanzas-Lombarte, Ángel ; Tan, Dun Xian ; García, José Joaquín ; Reiter, Russel J. / Melatonin's role as a co-adjuvant treatment in colonic diseases : A review. In: Life Sciences. 2017 ; Vol. 170. pp. 72-81.
@article{163792adb3ad4ca2abc1aaa419424b80,
title = "Melatonin's role as a co-adjuvant treatment in colonic diseases: A review",
abstract = "Melatonin is produced in the pineal gland as well as many other organs, including the enterochromaffin cells of the digestive mucosa. Melatonin is a powerful antioxidant that resists oxidative stress due to its capacity to directly scavenge reactive species, to modulate the antioxidant defense system by increasing the activities of antioxidant enzymes, and to stimulate the innate immune response through its direct and indirect actions. In addition, the dysregulation of the circadian system is observed to be related with alterations in colonic motility and cell disruptions due to the modifications of clock genes expression. In the gastrointestinal tract, the activities of melatonin are mediated by melatonin receptors (MT2), serotonin (5-HT), and cholecystokinin B (CCK2) receptors and via receptor-independent processes. The levels of melatonin in the gastrointestinal tract exceed by 10–100 times the blood concentrations. Also, there is an estimated 400 times more melatonin in the gut than in the pineal gland. Gut melatonin secretion is suggested to be influenced by the food intake. Low dose melatonin treatment accelerates intestinal transit time whereas high doses may decrease gut motility. Melatonin has been studied as a co-adjuvant treatment in several gastrointestinal diseases including irritable bowel syndrome (IBS), constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), Crohn's disease, ulcerative colitis, and necrotizing enterocolitis. The purpose of this review is to provide information regarding the potential benefits of melatonin as a co-adjuvant treatment in gastrointestinal diseases, especially IBS, Crohn's disease, ulcerative colitis, and necrotizing enterocolitis.",
keywords = "Crohn's disease, Gastrointestinal diseases, Irritable bowel syndrome, Melatonin, Necrotizing enterocolitis, Ulcerative colitis",
author = "Eduardo Esteban-Zubero and Laura L{\'o}pez-Pingarr{\'o}n and Alatorre-Jim{\'e}nez, {Mois{\'e}s Alejandro} and Purificaci{\'o}n Ochoa-Moneo and Celia Buisac-Ram{\'o}n and Miguel Rivas-Jim{\'e}nez and Silvia Cast{\'a}n-Ruiz and {\'A}ngel Anto{\~n}anzas-Lombarte and Tan, {Dun Xian} and Garc{\'i}a, {Jos{\'e} Joaqu{\'i}n} and Reiter, {Russel J}",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.lfs.2016.11.031",
language = "English (US)",
volume = "170",
pages = "72--81",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Melatonin's role as a co-adjuvant treatment in colonic diseases

T2 - A review

AU - Esteban-Zubero, Eduardo

AU - López-Pingarrón, Laura

AU - Alatorre-Jiménez, Moisés Alejandro

AU - Ochoa-Moneo, Purificación

AU - Buisac-Ramón, Celia

AU - Rivas-Jiménez, Miguel

AU - Castán-Ruiz, Silvia

AU - Antoñanzas-Lombarte, Ángel

AU - Tan, Dun Xian

AU - García, José Joaquín

AU - Reiter, Russel J

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Melatonin is produced in the pineal gland as well as many other organs, including the enterochromaffin cells of the digestive mucosa. Melatonin is a powerful antioxidant that resists oxidative stress due to its capacity to directly scavenge reactive species, to modulate the antioxidant defense system by increasing the activities of antioxidant enzymes, and to stimulate the innate immune response through its direct and indirect actions. In addition, the dysregulation of the circadian system is observed to be related with alterations in colonic motility and cell disruptions due to the modifications of clock genes expression. In the gastrointestinal tract, the activities of melatonin are mediated by melatonin receptors (MT2), serotonin (5-HT), and cholecystokinin B (CCK2) receptors and via receptor-independent processes. The levels of melatonin in the gastrointestinal tract exceed by 10–100 times the blood concentrations. Also, there is an estimated 400 times more melatonin in the gut than in the pineal gland. Gut melatonin secretion is suggested to be influenced by the food intake. Low dose melatonin treatment accelerates intestinal transit time whereas high doses may decrease gut motility. Melatonin has been studied as a co-adjuvant treatment in several gastrointestinal diseases including irritable bowel syndrome (IBS), constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), Crohn's disease, ulcerative colitis, and necrotizing enterocolitis. The purpose of this review is to provide information regarding the potential benefits of melatonin as a co-adjuvant treatment in gastrointestinal diseases, especially IBS, Crohn's disease, ulcerative colitis, and necrotizing enterocolitis.

AB - Melatonin is produced in the pineal gland as well as many other organs, including the enterochromaffin cells of the digestive mucosa. Melatonin is a powerful antioxidant that resists oxidative stress due to its capacity to directly scavenge reactive species, to modulate the antioxidant defense system by increasing the activities of antioxidant enzymes, and to stimulate the innate immune response through its direct and indirect actions. In addition, the dysregulation of the circadian system is observed to be related with alterations in colonic motility and cell disruptions due to the modifications of clock genes expression. In the gastrointestinal tract, the activities of melatonin are mediated by melatonin receptors (MT2), serotonin (5-HT), and cholecystokinin B (CCK2) receptors and via receptor-independent processes. The levels of melatonin in the gastrointestinal tract exceed by 10–100 times the blood concentrations. Also, there is an estimated 400 times more melatonin in the gut than in the pineal gland. Gut melatonin secretion is suggested to be influenced by the food intake. Low dose melatonin treatment accelerates intestinal transit time whereas high doses may decrease gut motility. Melatonin has been studied as a co-adjuvant treatment in several gastrointestinal diseases including irritable bowel syndrome (IBS), constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), Crohn's disease, ulcerative colitis, and necrotizing enterocolitis. The purpose of this review is to provide information regarding the potential benefits of melatonin as a co-adjuvant treatment in gastrointestinal diseases, especially IBS, Crohn's disease, ulcerative colitis, and necrotizing enterocolitis.

KW - Crohn's disease

KW - Gastrointestinal diseases

KW - Irritable bowel syndrome

KW - Melatonin

KW - Necrotizing enterocolitis

KW - Ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=85008957112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008957112&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2016.11.031

DO - 10.1016/j.lfs.2016.11.031

M3 - Review article

VL - 170

SP - 72

EP - 81

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

ER -